NYSE American - Delayed Quote USD

Can-Fite BioPharma Ltd. (CANF)

1.9800 +0.0600 (+3.13%)
At close: April 26 at 3:49 PM EDT
1.8300 -0.15 (-7.58%)
After hours: April 26 at 5:37 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
743.0000
743.0000
810.0000
853.0000
763.0000
Operating Expense
8,938.0000
8,938.0000
10,906.0000
13,695.0000
14,902.0000
Operating Income
-8,195.0000
-8,195.0000
-10,096.0000
-12,842.0000
-14,139.0000
Net Non Operating Interest Income Expense
492.0000
492.0000
206.0000
6.0000
-342.0000
Other Income Expense
69.0000
69.0000
-283.0000
221.0000
38.0000
Pretax Income
-7,634.0000
-7,634.0000
-10,173.0000
-12,615.0000
-14,443.0000
Net Income Common Stockholders
-7,634.0000
-7,634.0000
-10,173.0000
-15,205.0000
-15,158.0000
Diluted NI Available to Com Stockholders
-7,634.0000
-7,634.0000
-10,173.0000
-15,205.0000
-15,158.0000
Basic EPS
-3.00
--
-3.00
-9.00
-12.00
Diluted EPS
-3.00
--
-3.00
-9.00
-12.00
Basic Average Shares
4,261.1130
--
2,719.1540
1,843.5990
1,194.7040
Diluted Average Shares
4,261.1130
--
2,719.1540
1,843.5990
1,194.7040
Total Operating Income as Reported
-8,195.0000
-8,195.0000
-10,096.0000
-12,842.0000
-14,139.0000
Total Expenses
8,938.0000
8,938.0000
10,906.0000
13,695.0000
14,902.0000
Net Income from Continuing & Discontinued Operation
-7,634.0000
-7,634.0000
-10,173.0000
-12,615.0000
-14,443.0000
Normalized Income
-7,703.0000
-7,703.0000
-9,890.0000
-12,836.0000
-14,481.0000
Interest Income
506.0000
506.0000
222.0000
24.0000
44.0000
Interest Expense
--
--
--
--
363.0000
Net Interest Income
492.0000
492.0000
206.0000
6.0000
-342.0000
EBIT
-8,195.0000
-8,195.0000
-10,096.0000
-12,842.0000
-14,139.0000
EBITDA
-8,180.0000
-8,180.0000
-10,082.0000
-12,828.0000
-14,127.0000
Reconciled Depreciation
15.0000
15.0000
14.0000
14.0000
12.0000
Net Income from Continuing Operation Net Minority Interest
-7,634.0000
-7,634.0000
-10,173.0000
-12,615.0000
-14,443.0000
Total Unusual Items Excluding Goodwill
69.0000
69.0000
-283.0000
221.0000
38.0000
Total Unusual Items
69.0000
69.0000
-283.0000
221.0000
38.0000
Normalized EBITDA
-8,249.0000
-8,249.0000
-9,799.0000
-13,049.0000
-14,165.0000
12/31/2020 - 11/6/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BLRX BioLineRx Ltd.
0.6116
+6.31%
 
XTLB XTL Biopharmaceuticals Ltd.
2.4220
+0.92%
 
EVGN Evogene Ltd.
0.6251
-4.91%
 
ENLV Enlivex Therapeutics Ltd.
1.4400
-0.69%
 
PLUR Pluri Inc.
5.36
+2.23%
 
ELOX Eloxx Pharmaceuticals, Inc.
0.8058
+2.65%
 
SCNI Scinai Immunotherapeutics Ltd.
0.4578
+1.73%
 
PPBT Purple Biotech Ltd
0.4900
-2.00%
 
ORMP Oramed Pharmaceuticals Inc.
2.4600
+6.96%
 
NRBO NeuroBo Pharmaceuticals, Inc.
3.1400
+2.61%